EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real‐world cohort

Gregor Barth iD, Stefan Koch iD, Thorsten H Ecke iD

Cancer Cytopathology · 2026-08 · 134 (8)

DOI: 10.1002/cncy.70130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cytopathology, online erschienen am 09.07.2026. Verfasst von Gregor Barth und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Palliative Care, University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg, Ger…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Keratin-17, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Urine cytology is recommended for noninvasive detection of urothelial carcinoma (UC) but shows limited sensitivity, particularly in low‐grade disease. Keratin 17 (K17) has emerged as a promising immunocytochemical marker. This study evaluated the diagnostic performance and interobserver agreement of K17 in a routine setting.

Methods

This prospective cross‐sectional study included 184 urine samples from patients undergoing diagnostic evaluation for suspected UC. K17 immunocytochemistry was performed with a fully automated platform and independently evaluated by two blinded raters. Cytology was classified according to The Paris System for Reporting Urinary Cytology. UC status was determined by histology when available or by follow‐up and multidisciplinary assessment. Diagnostic accuracy was assessed by receiver operating characteristic (ROC) analysis; interobserver reliability was assessed with the Cohen κ and intraclass correlation coefficient (ICC). Multivariable logistic regression evaluated combined diagnostic approaches.

Results

K17 expression was significantly higher in UC than in non‐UC samples ( p < .001). Across raters, area under the ROC curve (AUC) values ranged from 0.68 to 0.71. Sensitivity was 52.9%–65.9%, with a specificity of 73.7%–82.8%. Sensitivity ranged from 45.5% to 54.5% for low‐grade tumors and from 57.7% to 73.1% for high‐grade tumors. In stage‐based analyses, sensitivity was 49.2%–61.5% for non–muscle‐invasive UC and 65%–80% for muscle‐invasive UC. Combining K17 with cytology numerically improved diagnostic discrimination (AUC value, 0.76; 95% CI, 0.69–0.83). Interobserver agreement was moderate to substantial (κ = 0.684; ICC, 0.653). Limitations included single‐center design, partial histological verification (81%), and post hoc optimized cutoffs.

Conclusions

K17 immunocytochemistry is a reproducible adjunct to urine cytology, with moderate diagnostic performance. It may warrant further evaluation as an adjunctive marker, particularly in low‐grade and cytologically equivocal cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorKeratin-17Urinary Bladder NeoplasmsCarcinoma, Transitional CellHumansFemaleMaleProspective StudiesCross-Sectional StudiesImmunohistochemistryAgedObserver VariationMiddle AgedCytodiagnosisROC CurveAged, 80 and overSensitivity and SpecificityReproducibility of Results

Stichwörter der Autor:innen

AB_563797biomarkerscarcinomacytodiagnosisimmunocytochemistrykeratin 17tumorsurinary bladder neoplasms

Substanzen

Biomarkers, TumorKeratin-17KRT17 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Oncology and Palliative Care, University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg, Germany.
  • Faculty of Health Sciences Brandenburg, Brandenburg, Germany.
  • Institute of Pathology, University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg, Germany.
  • Department of Urology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Department of Urology, Helios Hospital, Bad Saarow, Germany.

ORCID-Profile: Gregor Barth, Stefan Koch, Thorsten H Ecke

Zitieren

APA

Barth, G., Koch, S., & Ecke, T. H. (2026). Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real‐world cohort. Cancer Cytopathology, 134(8). https://doi.org/10.1002/cncy.70130

Vancouver

Barth G, Koch S, Ecke TH. Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real‐world cohort. Cancer Cytopathology. 2026;134(8). doi:10.1002/cncy.70130

BibTeX
@article{Barth2026,
  author = {Barth, Gregor and Koch, Stefan and Ecke, Thorsten H},
  title = {Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real‐world cohort},
  journal = {Cancer Cytopathology},
  year = {2026},
  volume = {134},
  number = {8},
  doi = {10.1002/cncy.70130}
}
Kostenlos starten →